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OBJECTIVE—To investigate the relationship between fasting
glucose levels, insulin resistance, and cognitive impairment in
old age. Diabetes is associated with cognitive impairment in
older people. However, the link between elevated fasting glucose
levels and insulin resistance in nondiabetic individuals, and the
risk of cognitive impairment is unclear.
RESEARCH DESIGN AND METHODS—We analyzed data
from, in total, 8,447 participants in two independent prospective
studies: the PROspective Study of Pravastatin in the Elderly at
Risk (PROSPER), 5,019 participants, aged 69–84 years, and the
Rotterdam Study, 3,428 participants, aged 61–97 years. Fasting
glucose levels were assessed at baseline in both studies; fasting
insulin levels were assessed in the Rotterdam Study only. Cog-
nitive function was assessed in both studies at baseline and
during follow-up.
RESULTS—Subjects with diabetes had impaired cognitive func-
tion at baseline. In contrast, in people without a history of
diabetes, there was no clear association between baseline fasting
glucose levels and executive function and memory, nor was there
a consistent relationship between elevated baseline fasting glu-
cose levels and the rate of cognitive decline in either cohort.
Insulin resistance (homeostasis model assessment index) was
also unrelated to cognitive function and decline.
CONCLUSIONS—Elevated fasting glucose levels and insulin
resistance are not associated with worse cognitive function in
older people without a history of diabetes. These data suggest
either that there is a threshold for effects of dysglycemia on
cognitive function or that factors other than hyperglycemia
contribute to cognitive impairment in individuals with frank
diabetes. Diabetes 59:1601–1607, 2010
D
iabetes has been shown to be associated with
an increased risk of dementia and impaired
cognitive function (1). Suggested biological
mechanisms that are involved in this relation
are accelerated cerebrovascular disease (1), accumulation
of advanced glycation end products (2), and reduced
amyloid -clearance through disturbing the role of the
insulin-degrading enzyme (3). The accumulating evidence
that diabetes is involved in a number of health problems,
ranging from retinopathy and cardiovascular symptoms to
neurological complications, has started a discussion about
the necessity to identify those people who are at increased
risk for diabetes (3–6).
Classifying people based on levels of fasting glucose to
indicate “impaired fasting glucose” has been suggested as
a possible tool for risk assessment of the development of
diabetes (5,6). However, the relationship between the
preceding stage of diabetes, when impaired fasting glu-
cose levels are present, and cognitive function has not
been comprehensively elucidated. A number of studies
have investigated the relationship between this “pre-dia-
betes” state and cognitive function but showed contradic-
tory or inconclusive results (7–9), possibly due to
relatively small sample sizes and limited numbers of
participants with an impaired fasting glucose level. Alter-
natively, peripheral insulin resistance that could underlie
the elevated fasting glucose levels in the pre-diabetes state
may contribute to impaired cognitive function (10,11).
Therefore, in this study we investigated the association
between fasting glucose levels and cognitive function and
decline in a large sample of 8,447 participants for whom
fasting glucose levels at baseline were available together
with longitudinal data from a dedicated neuropsychologi-
cal test battery. Additionally, we investigated the relation-
ship between insulin resistance (using the homeostasis
model assessment [HOMA] index) and cognitive function
and decline in 3,342 participants.
RESEARCH DESIGN AND METHODS
Populations. The PROspective Study of Pravastatin in the Elderly at Risk
(PROSPER) was a prospective multicenter randomized placebo-controlled
trial to assess whether treatment with pravastatin diminishes the risk of major
cardiovascular events in the elderly (12,13). Between December 1997 and May
1999, a total of 5,804 participants (aged 70–82 years) with preexisting vascular
disease or increased risk of such disease due to a history of smoking,
hypertension, or diabetes were recruited in Scotland, Ireland, and the Neth-
erlands. The institutional ethics review boards of all centers approved the
protocol, and all participants gave written informed consent. Participants with
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score 24) were excluded for inclusion in the study.
The Rotterdam Study is a large prospective population-based cohort study
that is conducted among all inhabitants aged 55 years of Ommoord, a district
of Rotterdam, the Netherlands (14). The medical ethics committee of the
Erasmus University of Rotterdam approved the study, and written informed
consent was obtained from all participants. Of 10,275 eligible subjects, 7,983
individuals (78%) participated in the baseline examinations between 1990 and
1993 (mean age 71  25 years, range 55–106 years). All participants were
interviewed at home and visited the research center for further examinations.
Fasting glucose levels. In PROSPER, fasting glucose levels were assessed at
baseline in 5,599 of the 5,804 participants. Of the 5,599 participants, 580 did
not have all cognitive function tests available at baseline. All of the resulting
5,019 participants had full data available for other cardiovascular risk factors
including BMI, systolic and diastolic blood pressure, and HDL cholesterol
levels at baseline. This resulted in a study sample of 5,019 participants for
PROSPER.
In the Rotterdam Study, fasting glucose levels were assessed at the third
survey in 3,795 participants. Of these participants, 3,664 were free of demen-
tia, and 3,550 of those had data available for other cardiovascular risk factors
including BMI, systolic and diastolic blood pressure, and HDL cholesterol
levels. Of these 3,550 participants, 122 did not have all cognitive function tests
available at the start of the third survey. This resulted in a study sample of
3,428 participants for the Rotterdam Study. Additionally, in 3,342 of these
3,428 participants, fasting insulin levels were assessed at the third survey.
In both the PROSPER and the Rotterdam sample, fasting glucose levels
were additionally measured during follow-up. There were 4,690 of the 5,019
participants in the PROSPER sample and 2,364 of the 3,428 participants in the
Rotterdam sample who underwent at least one additional measurement of
fasting glucose level in addition to the initial examination. These data were
used to study the variability of the fasting glucose levels over time and to
assess the appropriateness of using a single baseline fasting glucose measure-
ment to assess the relationship between fasting glucose and cognitive function
and decline.
History of diabetes. At baseline, history of diabetes was deﬁned by
self-reported history of diabetes (reporting the use of oral antidiabetes
medication, the use of insulin, treatment by diet, or registration by a general
practitioner as having diabetes) in both study samples.
Cognitive function. Global cognitive function was measured with the MMSE
(15) in both studies. In addition, a dedicated neuropsychological test battery
was used to assess executive function and memory. Executive function was
assessed with the Letter–Digit Substitution Task (LDST) (16) and the abbre-
viated Stroop test part 3 (17) in both studies, as well as with the Word Fluency
Test (WFT) (18) in the Rotterdam Study only. Memory was assessed with the
12-Picture Learning Test (12-PLT) immediate and delayed recall (19), in
PROSPER only.
Individual test scores were transformed into standardized z scores [z
score  (individual score – mean population score)/SD population score]. A
compound cognitive test score for global cognitive function was calculated by
averaging the z scores of the MMSE, the LDST, and the abbreviated Stroop
test part 3. A compound cognitive test score for the 12-PLT was calculated by
averaging the z scores of the 12-PLT immediate and the 12-PLT delayed recall
test.
In PROSPER, cognitive function was measured at six time points during
the study: before randomization, at baseline, after 9, 18, and 30 months, and
at the end of the study. The time point of the last measurement was different
for the participants and ranged from 36 to 48 months after baseline. Therefore,
we performed the analyses with their individual varying time point but report
the results for the mean of these time points (at 42 months). The prerandom-
ized measurement was discarded in the analyses to preclude possible learning
effects. This resulted in a mean follow-up of 3.2 years. Change in cognitive
function could be assessed in 4,767 participants for whom at least one
follow-up examination of cognitive function was available after the initial
measurement.
In the Rotterdam Study, cognitive function was assessed at the third survey
(1997–1999) and additionally at the fourth survey (2002–2004). This resulted in
a mean follow-up of 4.6 years. Of the 3,428 participants of the Rotterdam
sample who were present at the third survey, 2,601 remained in the study until
the end of follow-up (fourth survey) and were available for the assessment of
change in cognitive function.
Additional assessments. In both samples, level of education, BMI, systolic
and diastolic blood pressure, HDL cholesterol level, and APOE ε 4 carriership
were assessed at baseline (PROSPER) or at the third survey (Rotterdam
Study). Level of education was dichotomized into primary education or less
(low) and more than primary education (high) (Rotterdam Study) and into age
when leaving school 13 years (low) and age when leaving school 13 years
(high) (PROSPER).
Statistical analyses. The relationship between baseline (PROSPER) or third
survey (Rotterdam Study) fasting glucose levels and cognitive function and
decline was assessed by use of linear mixed models. Data from the PROSPER
sample and the Rotterdam Study sample were merged into one large sample
of 8,447 participants. All analyses were adjusted for age, sex, level of
education, study (PROSPER or Rotterdam Study), BMI, systolic and diastolic
blood pressure, HDL cholesterol level, APOE ε 4 carriership, country, use of
pravastatin, and, where appropriate, test version. Analyses were carried out
using the SPSS statistical package (release 12.0.1; SPSS, Chicago, IL).
Data on fasting glucose and fasting insulin levels from the Rotterdam Study
sample were used to calculate the degree of insulin resistance according to
HOMA (20). The HOMA index is calculated by dividing the product of fasting
levels of glucose and insulin by a constant and has been shown to correlate
well (r  0.82, P  0.0001) with the euglycemic-hyperinsulinemic clamp
method (21).
RESULTS
Table 1 shows the baseline characteristics of the total
sample and for participants with a history of diabetes at
baseline (PROSPER) or at the third survey (Rotterdam
Study). In PROSPER, the fasting glucose levels  SD
differed among the three countries from which the partic-
ipants were enrolled: Scotland 5.62  1.27, Ireland 5.09 
1.34), and the Netherlands 5.76  1.64 mmol/l. This
resulted in a lower mean fasting glucose level for the
PROSPER study sample compared with that of the Rotter-
dam Study sample. Participants with a history of diabetes
had a higher fasting glucose level, BMI, and systolic blood
pressure and lower levels of HDL cholesterol compared
with participants without a history of diabetes.
In PROSPER, fasting glucose levels were assessed dur-
ing follow-up after 3, 6, 12, 24, and 36 months, in addition
to the baseline assessment. In 3,491 participants without a
history of diabetes, fasting glucose levels were available at
baseline and after 36 months of follow-up. The mean
glucose levels slightly increased over time. The quintiles of
the mean fasting glucose  SD at baseline and after 36
months were 4.30  0.20 and 4.77  0.67 mmol/l for the
lowest quintile (quintile 1), 4.70  0.08 and 4.95  0.47
mmol/l for quintile 2, 5.00  0.08 and 5.21  0.67 mmol/l
for quintile 3, 5.33  0.11 and 5.46  0.70 mmol/l for
quintile 4, and 6.25  0.83 and 6.30  1.40 mmol/l for the
highest quintile (quintile 5). In the Rotterdam sample,
fasting glucose levels were assessed at the third survey as
well as at the end of follow-up (fourth survey) in 2,209
participants without a history of diabetes. The quintiles of
fasting glucose levels at the third survey and at the end of
follow-up were 4.82  0.24 and 5.07  0.39 mmol/l for the
lowest quintile (quintile 1), 5.20  0.08 and 5.36  0.42
mmol/l for quintile 2, 5.50  0.08 and 5.55  0.50 mmol/l
for quintile 3, 5.84  0.11 and 5.86  0.57 mmol/l for
quintile 4; and 6.73  .98 and 6.76  1.44 mmol/l for the
highest quintile (quintile 5).
Of the 8,447 participants who were present at baseline,
6,641 remained in the study sample until the end of
follow-up, 985 withdrew from the study, and 821 died
during follow-up. The 1,806 participants without a ﬁnal
examination comprised 20.8% of the participants without a
history of diabetes and 26.3% of the participants with a
history of diabetes at baseline (PROSPER) or at the third
survey (Rotterdam Study).
Figure 1A shows the relationship between fasting glu-
cose levels and cognitive function at baseline for the 8,447
participants of the merged study sample. Study-speciﬁc
quintiles of the distribution of fasting glucose levels in
participants without a history of diabetes were con-
structed to account for the differences in fasting glucose
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shown for quintiles of the distribution of fasting glucose
levels in participants without a history of diabetes and for
participants with a history of diabetes. In participants
without a history of diabetes, a rise in fasting glucose
levels in the nondiabetes range was not associated with
impairment in cognitive function, for any of the cognitive
tests. Additionally, we compared the cognitive test scores
at baseline for participants with and without a history of
diabetes (Fig. 1A) and showed that participants with a
history of diabetes had worse cognitive function across
the majority of tests at baseline when compared with
participants without a history of diabetes (P  0.05 for all
tests except for the WFT in the Rotterdam Study sample).
In the longitudinal analyses of the study population,
there was no clear association between baseline fasting
glucose levels and change in cognitive function during
follow-up in participants without a history of diabetes
(Fig. 1B). In the PROSPER sample, higher levels of fasting
glucose were associated with a decreased rate of decline
on the 12-PLT (Ptrend  0.039), but this was not seen for
any of the other cognitive tests. Furthermore, participants
with a history of diabetes did not show an increased rate
of decline for any of the cognitive tests.
Additionally, we assessed the relationship between in-
sulin resistance and cognitive function and decline for the
3,342 participants of the Rotterdam Study sample for
whom fasting insulin levels were available (Fig. 2A). The
HOMA that was calculated for these participants was
correlated with the fasting glucose levels (r  0.54, P 
0.001), although the overlap between quintiles of the
HOMA index and quintiles of fasting glucose levels was
limited: only 35% of the participants without a history of
diabetes were in the same quintile of the distribution for
both fasting glucose and HOMA index. The relationship
between insulin resistance and cognitive function was in
accordance with ﬁndings on fasting glucose levels and
cognitive function: in participants without a history of
diabetes, rising insulin resistance was not associated with
cognitive function. Similarly, there was no clear relation-
ship between levels of insulin resistance and change in
cognitive function during follow-up (Fig. 2B). When the
data from the PROSPER sample and the Rotterdam Study
sample were analyzed separately, the ﬁndings were con-
sistent with the results of the merged sample of 8,447
participants.
DISCUSSION
Our study shows that, in an unprecedented large number
of individuals from two independent prospective studies,
higher levels of fasting glucose in the absence of a history
of diabetes are not associated with cognitive function or
cognitive decline. Furthermore, there was no association
between insulin resistance (HOMA index) and cognitive
function and decline in people without a history of diabe-
tes. However, participants with a history of diabetes did
have worse cognitive function at baseline than those
without diabetes, although the magnitude of the observed
effects was relatively small.
The results of our analyses do not fully correspond with
previous ﬁndings in the Rotterdam Study, in which diabe-
tes was found to be related to an increased risk of
developing dementia (22). Although our data show that
those with a history of diabetes have worse cognitive
function at baseline than those without, one could argue
TABLE 1
Baseline characteristics
Total sample
History of diabetes
No Yes
PROSPER
n 5,019 4,476 543
Age (years) 75.3  3.3 75.3  3.4 75.2  3.2
Female sex 2,630 (52) 2,387 (53) 243 (45)
Low level of education 122 (2) 99 (2) 23 (4)
MMSE score (points) 28.1  1.5 28.1  1.5 28.0  1.6
Fasting glucose levels (mmol/l) 5.45  1.41 5.14  0.78 8.02  2.43
BMI (kg/m
2) 26.9  4.2 26.7  4.1 28.0  4.3
Systolic blood pressure( mmHg) 155  22 154  22 158  22
Diastolic blood pressure (mmHg) 84  11 84  11 84  11
HDL cholesterol (mmol/l) 1.28  0.35 1.29  0.35 1.17  0.31
APOE ε 4 carriership 1,192 (24) 1,091 (24) 101 (19)
Rotterdam Study
n 3,428 3,116 312
Age (years) 71.8  6.6 71.6  6.5 73.8  6.8
Female sex 1,975 (58) 1,817 (58) 158 (51)
Low level of education 515 (15) 472 (15) 43 (14)
MMSE score (points) 27.8  1.8 27.8  1.8 27.6  1.9
Fasting glucose levels (mmol/l) 5.88  1.35 5.65  0.93 8.12  2.43
BMI (kg/m
2) 26.9  3.9 26.8  3.9 27.9  4.4
Systolic blood pressure( mmHg) 143  21 143  21 150  21
Diastolic blood pressure (mmHg) 75  11 75  11 75  11
HDL cholesterol (mmol/l) 1.39  0.39 1.41  0.39 1.26  0.39
APOE ε 4 carriership 915 (27) 838 (27) 77 (25)
Fasting insulin levels (mU/l)* 11.2  7.8 10.9  7.1 14.6  12.4
Insulin resistance, HOMA* 3.07  2.94 2.82  2.25 5.58  6.17
Data are means  SD or n (%). *Fasting insulin levels were available for 3,342 participants in the Rotterdam Study.
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previous report of an almost twofold increased risk of
dementia for people with diabetes (22). It is possible that
the measurement of cognitive function compared with the
assessment of participants with dementia in the Rotter-
dam Study underlies this discrepancy. In the Rotterdam
Study, we are able to continuously monitor the total
cohort for incident dementia through computerized link-
age between the study database and digitalized medical
records from the general practitioners and the Regional
Institute for Outpatient Mental Health Care. In contrast, in
the Rotterdam sample, cognitive function assessments
were performed with a 4.6-year interval, which could have
led to selective nonparticipation of those in whom demen-
tia was diagnosed between cognitive examinations (n 
85) and did not visit the research center for the follow-up
assessment.
Furthermore, a previous report from the Nurses’ Health
Study showed that higher insulin levels in nondiabetic
participants were related to faster cognitive decline (23).
These results are not in agreement with our results on the
relationship between insulin resistance and cognitive de-
cline in the Rotterdam Study sample. The prolonged length
of follow-up (10 years compared with 4.6 years) in the
Nurses’ Health Study could have affected these results, as
the effect of insulin resistance on cognitive function might
be long-term. On the other hand, results from the ongoing
Memory in Diabetes (MIND) substudy of the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) trial
showed that higher A1C but not fasting plasma glucose
levels was associated with worse cognitive function in a
sample of almost 3,000 participants (24), which is in line
with our results.
In individual participants, diabetes and impaired fasting
glucose levels often co-occur with other cardiovascular
risk factors. The metabolic syndrome is seen as a cluster-
ing of a number of these risk factors (abdominal obesity,
hypertriglyceridemia, low HDL cholesterol, hypertension,
and hyperglycemia) and is the subject of an ongoing
discussion on the clinical use of the syndrome and its
individual components in establishing the risk of cardio-
vascular disease and diabetes (25). Other studies have
suggested a relationship between the metabolic syndrome
and the risk of cognitive impairment and dementia (26–
28). In our study, the clustering of these factors of the
metabolic syndrome with the fasting glucose levels could
have inﬂuenced our results. However, adjustment for BMI,
systolic and diastolic blood pressure, and HDL cholesterol
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FIG. 1. A: Fasting glucose levels and cognitive function. z scores (SEM) for different cognitive test scores are plotted for study-speciﬁc quintiles
of fasting glucose levels in nondiabetic participants (from lowest [quintile 1] to the highest [quintile 5] levels of fasting glucose) and for
participants with a history of diabetes (DM). P values reﬂect the trend over the quintiles of fasting glucose levels, as well as the difference
between participants without a history of diabetes (n  7,592) and participants with a history of diabetes (n  855). Estimates are based on the
maximum number of participants available per cognitive test: global cognitive function (n  8,447), WFT (n  3,518), and 12-PLT (n  5,223).
B: Fasting glucose levels and change in cognitive function. z scores (SEM) represent annual change in cognitive test scores for study-speciﬁc
quintiles of fasting glucose levels in nondiabetic participants (from lowest [quintile 1] to the highest [quintile 5] levels of fasting glucose) and
for participants with a history of diabetes. P values reﬂect the trend over the quintiles of fasting glucose levels, as well as the difference between
participants without a history of diabetes (n  6,649) and participants with a history of diabetes (n  719). Estimates are based on the maximum
number of participants available per cognitive test: global cognitive function (n  7,368), WFT (n  2,639), and 12-PLT (n  4,960). Linear mixed
models were used, adjusted for age, sex, level of education, study (PROSPER or Rotterdam Study), BMI, HDL level, systolic blood pressure,
diastolic blood pressure, country, treatment group, and test version where applicable.
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these covariates.
Furthermore, the participants in PROSPER were in-
cluded based on their increased cardiovascular risk pro-
ﬁle: having either preexisting vascular disease or
increased risk of such disease due to a history of smoking,
hypertension, or diabetes. The known association between
these cardiovascular risk factors and cognitive function
and decline might have interfered with our investigation of
the relationship between fasting glucose levels and cogni-
tive function and decline. However, when we excluded the
2,823 participants in PROSPER who had a history of
vascular disease from the sample of 5,019 participants, the
relationship between fasting glucose levels and cognitive
function at baseline did not markedly differ from our
ﬁndings in the total sample: there was no clear relation-
ship between fasting glucose levels and cognitive function
in participants without a history of vascular disease.
Moreover, after exclusion of the 2,823 participants, there
was no signiﬁcant relationship anymore between history
of diabetes and baseline global cognitive function. The
relationship between fasting glucose levels and change in
cognitive function did not markedly change after exclu-
sion of the participants with a history of vascular disease.
The same was seen for the analyses on the relationship
between history of diabetes and change in cognitive
function. Therefore, we do not think that the inclusion
of participants with preexisting vascular disease in
PROSPER has masked a possible association between
fasting glucose and insulin resistance on cognitive
function.
We used fasting insulin levels that were available for
almost the entire sample of the Rotterdam Study to
calculate the HOMA index as a measure of insulin resis-
tance to further investigate the relationship between glu-
cose metabolism and cognitive function. However, the
relationship between insulin resistance and cognitive func-
tion and decline showed similarities with the association
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FIG. 2. A: Insulin resistance (HOMA) and cognitive function in the Rotterdam Study. z scores (SEM) for different cognitive test scores are plotted
for quintiles of insulin resistance (HOMA) in nondiabetic participants (from lowest [quintile 1] to the highest [quintile 5] levels of insulin
resistance [HOMA]) and for participants with a history of diabetes (DM). P values reﬂect the trend over the quintiles of fasting glucose levels,
as well as the difference between participants without a history of diabetes (n  3,039) and participants with a history of diabetes (n  303).
Estimates are based on the maximum number of participants available per cognitive test: global cognitive function (n  3,342) and WFT (n 
3,424). B: Insulin resistance (HOMA) and change in cognitive function. z scores (SEM) represent annual change in cognitive test scores for
quintiles of insulin resistance (HOMA) in nondiabetic participants (from lowest [quintile 1] to the highest [quintile 5] levels of insulin resistance
[HOMA]) and for participants with a history of diabetes. P values reﬂect the trend over the quintiles of fasting glucose levels, as well as the
difference between participants without a history of diabetes (n  2,331) and participants with a history of diabetes (n  203). Estimates are
based on the maximum number of participants available per cognitive test: global cognitive function (n  2,534) and WFT (n  2,567). Linear
mixed models were used, adjusted for age, sex, level of education, BMI, HDL level, systolic blood pressure, and diastolic blood pressure.
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decline: in participants without a history of diabetes,
insulin resistance was not associated with cognitive func-
tion or decline.
Previous population-based studies that investigated the
relationship between glucose metabolism and cognitive
functions suggested a number of possible biological mech-
anisms that could be involved, ranging from accumulation
of advanced glycation end products (2) and accelerated
cerebrovascular disease (1) to the role of the insulin-
degrading enzyme on amyloid  metabolism (3). Although
it is difﬁcult to address the role of these suggested
mechanisms, our study of 8,000 participants shows that
the effect of increased fasting glucose levels on cognitive
function seems to be long-term and independent of other
cardiovascular risk factors like BMI, blood pressure, and
HDL cholesterol levels.
The observed differences in cognitive test scores be-
tween people with and without a history of diabetes were
relatively moderate and may therefore lack clinical signif-
icance for individuals. However, small effect sizes do not
automatically imply irrelevance of the observed effect, as
small effects on the group level can indeed represent large
effects for a number of participants.
In the analyses of the annual decline in cognitive func-
tion, the PROSPER sample failed to show a clear decline
in MMSE score over time, although this was seen in the
Rotterdam sample with participants of comparable age. It
is possible that a potential learning effect of the MMSE had
a higher impact on the PROSPER sample compared with
the Rotterdam Study sample because of the shorter time
span between cognitive measurements (19). Additionally,
the selection criteria for participants in PROSPER (base-
line MMSE score  24) may have resulted in a sample of
participants with slightly better cognitive function, which
is also represented in the difference in MMSE scores of
both samples at baseline and might have had an effect on
the annual decline of MMSE score that was measured in
PROSPER.
The strengths of this study consist of the prospective
design, the large number of participants in both studies,
and the dedicated neuropsychological test battery that
was used in both samples. Furthermore, we had the
possibility of studying the variability of fasting glucose
levels during follow-up and of examining the appropriate-
ness of using a single measurement of fasting glucose level
to assess the association between fasting glucose levels
and cognitive function and decline. A large variation in
fasting glucose levels over time could have disturbed our
analyses through the phenomenon of “regression-to-the-
mean.” However, the levels of fasting glucose during
follow-up did not materially differ from the baseline or
third survey in both study samples. Therefore, we decided
to use the baseline or third survey fasting glucose mea-
surement in our analyses.
Some limitations need to be addressed. Participants
who were present at baseline but did not undergo fol-
low-up examinations were predominantly present in the
group with a history of diabetes. They had worse cognitive
function at baseline compared with the participants who
stayed in the study until the end of follow-up. This
selective attrition of participants with relatively high levels
of fasting glucose and concurrent low levels of cognitive
function could have resulted in an underestimation of our
estimates of cognitive decline for participants with a
history of diabetes. We also recognize that some individ-
uals with diabetes would have been missed because of
lack of oral glucose tolerance testing. More importantly,
undiagnosed diabetes would be more prevalent in those in
the higher quintiles for fasting glucose and would have
biased the study toward an association of higher quintiles
and cognitive decline, not the other way around. Thus,
lack of oral glucose tolerance testing does not negate our
ﬁndings; rather it gives us added conﬁdence that our
observations are valid.
In conclusion, elevations in fasting glucose levels are
not clearly associated with impaired cognitive function or
with an accelerated rate of cognitive decline in partici-
pants without a history of diabetes. Furthermore, there
was no clear relationship between insulin resistance
(HOMA index) and cognitive function and decline in
participants without a history of diabetes. These data
suggest that cognitive decline accelerates strongly once a
person is diabetic but not with lesser degrees of dysglyce-
mia. As a result, preventing individuals at risk from
developing diabetes through lifestyle changes may also
lead to large societal gains by preventing such individuals
from undergoing accelerated cognitive decline.
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